Positive data from study of Alpha IMS in Retinitis Pigmentosa-Retina Implant

Retina Implant has announced that Dr. Helmut Sachs, senior consultant and head of the Department of Ophthalmology, Clinic Dresden-Friedrichstadt, Germany presented Retinitis Pigmentosa patient outcomes at one year post-implantation of the CE marked Alpha IMS subretinal microchip at the American Academy of Ophthalmology annual meeting. Dr. Sachs' presentation, "Subretinal Implantation and Functional Results of the Alpha IMS Chip to Restore Vision in 26 Blind Retinitis Pigmentosa Patients," reviewed patients' every day visual experiences after implantation with the Alpha IMS subretinal microchip. Key findings included improved ability to detect light and grating acuity in 85 percent and 54 percent of patients, respectively. The study authors concluded that implantation of the Alpha IMS is safe, and that the majority of patients demonstrated a marked improvement in their visual capabilities, including recognition of shapes, objects or details in daily life.